Results 121 to 130 of about 460,462 (263)
Oncogenes and Oncofetal Proteins [PDF]
QJM: An International Journal of Medicine, 1985 openaire +1 more source
Advanced Science, EarlyView.Through integrated proteomic and metabolomic profiling, Zhao et al. identified three molecular subtypes of high‐grade serous ovarian cancer. The high‐risk subtype exhibits activated arachidonic acid metabolism and cyclooxygenase‐2 overexpression. This metabolic axis promotes M2‐like macrophage infiltration, which contributes to platinum resistance ...
Yuxi Zhao +11 more
wiley +1 more source
Heterogeneous nuclear ribonucleoprotein K in cancer biology and its therapeutic applications (Review). [PDF]
Mol Med RepQin Y, Zhou Y.
europepmc +1 more source
Advanced Science, EarlyView.In TP53mut GBM cells, reduced P53 function is associated with increased TET1 expression. Genetic or pharmacological inhibition of TET1 correlates with genome fragility, including DNA damage, cellular senescence, telomere shortening, and reactive oxygen species accumulation, which may contribute to increased efficacy of antitumor therapy.
Zhuonan Pu +12 more
wiley +1 more source
CRISPR Interference to Inhibit Oncogenes for Cancer Therapy. [PDF]
Int J Mol SciGuo B.
europepmc +1 more source
Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment
Advanced Science, EarlyView.This study introduces an innovative strategy for the tumor‐selective catalytic degradation of oncogenic non‐coding RNA by interfacing a ribonuclease‐recruiting small molecule (RIBOTAC) with an EGFR‐targeting nanobody via a CTSB (Cathepsin B)‐responsive linker.
Tianli Luo +15 more
wiley +1 more source
Targeting QRICH1 suppresses epithelial-mesenchymal transition and tumor growth in liver cancer through the Connexin43/USP1 mediated Snail1 stabilization. [PDF]
Int J Biol SciPark SY, Shim BS, Kim B, Kim SH.
europepmc +1 more source